SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. All participants will receive FHD-286 orally once daily in 21-day cycles. The primary objective is to assess the objective response rate of FHD-286 in this population. The names of the study drug involved in this study is: • FHD-286 (a small-molecule SMARCA4/2 ATPase (BRG1 and BRM) inhibitor targeting the SWI/SNF chromatin remodeling complex (also known as the BAF complex)

NCT Number	NCT07551635
Lead Sponsor	Dana-Farber Cancer Institute Collaborators: Foghorn Therapeutics Inc.
Conditions	Small Cell Lung Cancer
Enrollment	20 participants
Start Date	2026-09-04
Primary Completion	2028-01-31 (estimated)
Study Completion	2029-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-27